Nebenwirkungen · Jorveza
Jorveza 0.2 mg/mL oral suspension · Abschnitt 4.8 · PDF-Seite 18
HOS-140401 · Präparat HOS-098512
MedDRA system organ class Adverse reactions Immune system disorders Increased risk of infection Endocrine disorders Cushing’s syndrome, adrenal suppression, growth retardation in children Metabolism and nutrition disorders Hypokalaemia, hyperglycaemia Psychiatric disorders Depression, irritability, euphoria, psychomotor hyperactivity, aggression Nervous system disorders Pseudotumor cerebri including papilloedema in adolescents Eye disorders Glaucoma, cataract (including subcapsular cataract), blurred vision, central serous chorioretinopathy (CSCR) (see also section 4.4) Vascular disorders Increased risk of thrombosis, vasculitis (withdrawal syndrome after long-term therapy) Gastrointestinal disorders Duodenal ulcers, pancreatitis, constipation Skin and subcutaneous tissue Allergic exanthema, petechiae, delayed wound healing, disorders contact dermatitis, ecchymosis Musculoskeletal and connective Muscle and joint pain, muscle weakness and twitching, tissue disorders osteoporosis, osteonecrosis General disorders and administration Malaise site conditions
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-24T09:00:00Z · SHA-256 80168fbedb4b00c0a889b8b0862fc6573379497e66db270467d63b263635ec1d · Passage b48552445f5e1b0c8d64b7e49219dfccee6c479a80a0c189be2a23f6be02ae98 · Zeichen 4241–5809 im Abschnitt